

Anti-Cisplatin modified DNA [CP9/19]

Catalogue number: 151464

Sub-type: Primary antibody

Images:

Contributor

Inventor: Michael Tilby

Institute: The Institute of Cancer Research; Newcastle University

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-Cisplatin modified DNA [CP9/19]

Alternate name:

Class: Monoclonal

Conjugate: Unconjugated

Description: Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG2a

Reactivity:

Selectivity:

Host: Rat

Immunogen: Cisplatin modified native DNA

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls: RNA/DNA

Bacterial resistance:

Selectable markers:

Additional notes:

Target details

Target: Cisplatin modified native DNA

Target alternate names:

Target background: This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.

Molecular weight:

Ic50:

Applications

Application: ELISA ; FACS ; IHC ; IP ; DB

Application notes:

Handling

Format: Liquid

Concentration: 1 mg/ml

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide

Storage conditions: -15° C to -25° C

Shipping conditions: Shipping at 4° C

Related tools

Related tools: Anti-Cisplatin modified DNA, Recombinant [CP9/19]

References

References: Littlewood et al. 1995. Nucleic Acids Res. 23(10):1686-90. PMID: 7784172. ; A modified

oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. ; Morgenstern et al. 1990. Nucleic Acids Res. 18(12):3587-96. PMID: 2194165. ; Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

CancerTools.org